Tucatinib approval by EMA expands options for HER2-positive locally advanced or metastatic breast cancer

por Corti, C., Criscitiello, C.
Publicado 2021

How I treat HER2-positive early breast cancer: how long adjuvant trastuzumab is needed?

por Morganti, S., Bianchini, G., Giordano, A., Giuliano, M., Curigliano, G., Criscitiello, C.
Publicado 2022

Tumour dormancy and clinical implications in breast cancer

por Gelao, L, Criscitiello, C, Fumagalli, L, Locatelli, M, Manunta, S, Esposito, A, Minchella, I, Goldhirsch, A, Curigliano, G
Publicado 2013

Impact of COVID-19 on social media as perceived by the oncology community: results from a survey in collaboration with the European Society for Medical Oncology (ESMO) and the Onco...

por Morgan, G., Tagliamento, M., Lambertini, M., Devnani, B., Westphalen, B., Dienstmann, R., Bozovic-Spasojevic, I., Calles, A., Criscitiello, C., Curioni, A., Garcia, A.M., Lamarca, A., Pilotto, S., Scheffler, M., Strijbos, M., Wong, R., de Azambuja, E., Peters, S.
Publicado 2021